How should I manage rectal bleeding in a patient with rectal cancer undergoing concurrent chemoradiation who has had seven days of rectal bleeding and a decrease in hemoglobin?

Management of Rectal Bleeding During Concurrent Chemoradiation for Rectal Cancer

In your patient with rectal bleeding during active chemoradiation and a modest hemoglobin drop (13.5→12 g/dL), you should first perform urgent endoscopic evaluation to exclude tumor progression or other causes, then reassure the patient if bleeding is not severely affecting quality of life, as this hemoglobin drop does not yet require intervention beyond observation. 1

Initial Assessment and Diagnostic Approach

You must arrange appropriate endoscopic investigation immediately because you cannot assume the bleeding is simply radiation-induced—it could represent tumor progression, ulceration, or other pathology 1. The 2025 British Society of Gastroenterology guidelines explicitly state this as their first clinical practice guidance point.

During concurrent chemoradiation, bleeding can arise from:

• The tumor itself (potentially responding to treatment or progressing)
• Early radiation-induced mucosal injury
• Treatment-related ulceration
• Combination of factors

Perform flexible sigmoidoscopy or colonoscopy with digital rectal examination. Do not biopsy if you see typical radiation proctopathy appearance—biopsy in ischemic, irradiated tissue risks necrosis and perforation 1.

Risk Stratification Based on Your Patient's Presentation

Your patient's hemoglobin dropped only 1.5 g/dL over 7 days (13.5→12 g/dL). This is not yet clinically significant bleeding requiring aggressive intervention. The guidelines are clear: if bleeding is not affecting quality of life and malignancy has been excluded, reassurance and explanation of natural history is appropriate—intervention is not required 1.

When Intervention IS Required:

• Transfusion-dependent bleeding
• Recurrent anemia requiring repeated treatment
• Bleeding severely affecting quality of life (e.g., fecal incontinence with blood, interference with daily activities)
• Hemodynamic instability

Your patient does not meet these criteria yet.

Conservative Management Strategy (Appropriate for Your Patient)

Step 1: Medication Review

Stop anticoagulants or antiplatelet agents if medically possible—this alone often reduces bleeding to tolerable levels 1.

Step 2: Bowel Function Optimization

Optimize irregular bowel function with stool softeners and regularity measures. This frequently reduces bleeding sufficiently that it no longer affects quality of life 1.

Step 3: Monitor Hemoglobin

Continue weekly hemoglobin checks. Intervention becomes necessary if:

• Hemoglobin drops below 10 g/dL
• Patient becomes symptomatic (fatigue, dyspnea, tachycardia)
• Bleeding rate accelerates

If Bleeding Worsens: Escalation Algorithm

First-Line Medical Therapy

Sucralfate enemas are the recommended first-line treatment for problematic bleeding 1:

• 2 g sucralfate suspension in 30-50 mL tap water
• Administered rectally via soft Foley catheter
• Patient rolls 360 degrees to coat entire rectal surface
• Lying prone best covers anterior wall (usual bleeding site)
• Retain 20 minutes minimum
• Use twice daily initially; once daily for maintenance
• Can be used long-term or as bridge to definitive therapy

Second-Line Options (If Medical Therapy Fails)

Consider endoscopic therapy only after informed consent discussing risks of intervention in ischemic tissue 1:

• Argon plasma coagulation (most common)
• Bipolar electrocautery for visible vessels
• Radiofrequency ablation

Third-Line (Refractory Cases)

Hyperbaric oxygen therapy for persistent bleeding despite topical and endoscopic interventions 2, 3.

Critical Pitfalls to Avoid

1. Do not assume all bleeding is radiation-induced during active treatment—tumor progression or other pathology must be excluded first 1

2. Do not perform biopsies of radiation proctopathy—interventions in ischemic tissue may not heal and can cause necrosis/perforation 1

3. Do not rush to aggressive intervention for modest hemoglobin drops—your patient's 1.5 g/dL decrease over 7 days does not warrant immediate endoscopic therapy

4. Do not forget that 75% of patients with rectal bleeding at Week 1 of chemoradiation improve by Week 3 4—this may be self-limiting

Specific Recommendations for Your Patient

1. Perform flexible sigmoidoscopy within 24-48 hours to exclude tumor progression or other pathology
2. If endoscopy shows early radiation changes or tumor response without active arterial bleeding: Reassure patient, optimize bowel function, review medications
3. Monitor hemoglobin weekly—current drop (13.5→12) does not require transfusion or aggressive intervention
4. Consider sucralfate enemas if bleeding persists or worsens, affecting quality of life
5. Reserve endoscopic hemostasis for hemoglobin <10 g/dL, transfusion requirement, or severe quality of life impact

The natural history during concurrent chemoradiation often shows initial bleeding that stabilizes or improves as treatment progresses 4. Your patient's modest hemoglobin drop suggests this is not yet severe bleeding requiring aggressive management.